Revance Therapeutics (RVNC) Tops Q3 EPS by 20c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/24/2026
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Oil drops more than $2 despite new US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wattmore and Eos Energy strike non-exclusive storage software deal
- Grand Canyon Education places CFO on leave amid stock trade probe
- S&P 500, Nasdaq end down on tech stocks, investors weigh Iran moves
- Funds sell $44bn in semiconductors on AI concerns
- RUM Group signs $13.7 billion GPU services deal, issues warrants
Revance Therapeutics Releases Third Quarter 2015 Results
November 9, 2015 4:03 PM ESTNEWARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (NASDAQ: RVNC), a specialty biopharmaceutical company developing botulinum toxin products for use in aesthetic and therapeutic indications, announced today results for the third quarter ended September 30, 2015.
Recent Highlights
Reported positive top line interim data from BELMONT Phase 2 Active Comparator Trial of RT002 injectable for the treatment of glabellar (frown) lines: RT002 investigational drug product candidate, RTT150 (Botulinum Toxin Type A) for Injection, demonstrated a six-month median duration based upon at least 1-point improvement in glabellar lines at maximum contraction (frown) on... MoreRevance Therapeutics Announces Closing of Public Offering of Common Stock
November 9, 2015 12:11 PM ESTNEWARK, Calif., Nov. 9, 2015 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq: RVNC) today announced the closing of its underwritten public offering of 3,737,500 shares of its common stock at a price to the public of $36.00 per share, which includes the exercise in full by the underwriters of their option to purchase 487,500 additional shares of common stock. The net proceeds from the sale of the shares, after deducting the underwriters' discounts and other estimated offering expense payable by Revance, will be approximately $126 million.
Cowen and Company, LLC, Piper Jaffray & Co., and Guggenheim Securities, LLC acted as... More
